Objectives: To assess the relationship and the directionality between mobility and cognitive performance.
C ognitive impairment and the subsequent development of dementia likely result from the culmination of several pathologic processes that begin decades before the symptoms become clinically apparent. 1 Mobility loss is often a more readily clinically recognizable medical condition that frequently occurs in an age-related manner. 2 The loss of one's cognitive abilities and mobility poses a serious threat to the well-being and the ability of older adults to remain independent, and are among the greatest fears of individuals as they age.
Adding to the complexity of age-related functional loss is that in many cases cognition and mobility appear to decline in a complex, interactive, and likely bidirectional relationship. The ability to perform activities of daily living, particularly the more complex activities such as shopping, preparing meals, using appliances, and balancing a checkbook, rely a great deal on maintaining cognitive and mobility function. The recently proposed Central Benefit Model of exercise in falls prevention provides a biopsychological approach to understanding the intricate association between cognitive and physical dysfunction. 3 According to this model, reduced executive functioning may lead to gait and balance problems as a direct effect of impaired attention, central processing, and execution of postural response or through the loss of motivation leading to reduced physical activity participation and in turn to muscle waste and weakness. A feedback loop is proposed, with impaired mobility and loss of motivation potentially leading to further cognitive decline. 3 Models examining mobility decline suggest that agerelated changes in muscle cells and loss of strength lead to decreased mobility performance measured by a slower gait and poor balance, and finally difficulties performing normal daily activities (ie, mobility-related disability). 4 In this model, cognitive impairment may play the role of a risk factor, a moderator, or the outcome of mobility decline; thus, it is important to better understand the relationship between cognitive function and mobility dysfunction at its different stages. Whereas cognitive impairment has been linked to measures of mobility dysfunction spanning the disablement process, from poor muscle strength, 5 to slower gait, 6 poor balance, 7 and mobility, 8 many previous studies have focused on later stages of disability, 9, 10 or failed to address the importance of the relationship between the stage of mobility dysfunction and cognitive abilities. In addition, although there seems to be more evidence for cognitive loss preceding or concurring physical loss, 11 recent reports of a reverse association 10, 12, 13 suggest that the directionality of the cognition-mobility association remains unclear as do the mechanisms linking the 2 processes, which are likely complex and involve behavioral, stress-related, and inflammatory pathways. [14] [15] [16] Understanding the interconnectedness between mobility and cognitive impairment and the sequence in which loss occurs are important as the stage of mobility dysfunction may provide valuable information for the risk, the diagnosis, and the prognosis of significant neurocognitive disorders. In the same vein, the presence of early cognitive impairment may indicate the need for interventions to prevent the development of future mobility impairments. To aid these efforts, the current cross-sectional study was designed to assess whether and how the stage of mobility dysfunction relates to cognitive performance and to investigate the directionality of the cognition-mobility association in a relatively large and ethnically diverse sample of community-dwelling older adults.
METHODS
Study participants were community-dwelling adults aged 40 years and older recruited to participate in research projects studying (1) the use of screening tests to detect cognitive and functional impairment in a multicultural community and (2) corresponding biomarkers of cognitive decline at the New York University (NYU) Langone Medical Center between February 2012 and March 2014. Participants were recruited by word-of-mouth, solicitation at educational seminars on dementia and other age-related conditions, collaborations with local senior centers, housing projects, churches, and other organizations advocating for the betterment of seniors, particularly minorities and other disadvantaged groups, and advertisements to individuals registered into the Research Match database maintained by the NYU Clinical Science and Translational Institute. Exclusion criteria included a primary language other than English or Spanish and an established diagnosis of a primary Axis I psychiatric (eg, schizophrenia, bipolar disease) or degenerative neurological (ie, Parkinson disease, amyotrophic lateral sclerosis) disorder that could impact cognitive and/or physical performance or cooperation with study procedures. A total of 350 participants were evaluated in 1 of 2 settings: a clinic visit in our research lab or at the location they were recruited initially (eg, senior center, church). All procedures were identical, and data collected included sociodemographic characteristics and cognitive, physical, emotional, and functional aspects of health using standardized, portable assessment tools. Of these, 332 (95%) participants had valid data on mobility, with all but 5 participants also contributing data on cognitive function. A total of 327 participants were therefore included in the data analysis. The protocol was approved by the NYU Institutional Review Board, and all study participants provided signed informed consents. Whereas one of the research projects from which participants were recruited in the current study used an inclusion cutoff age of 40 years (to allow for a representative population sample to map the aging brain), most participants were aged 50 years and older (312 out of 327 or 95%). With the exception of 1 study in which a quarter were recruited to have MCI, participants were not targeted on the basis of their cognitive status.
Cognitive Function
Global cognitive function was measured using the Montreal Cognitive Assessment (MoCA), 17 a tool validated for use in older adults. The MoCA assesses performance on 10 individual items for a total of 30 points, with higher scores indicating a better performance. To account for educational differences, an extra point was allowed for those with r12 years of education. These items measure different cognitive aspects including visuospatial skills, executive function, attention, language, memory, and orientation, with the total score used as a measure of the global cognitive performance. The total MoCA score was used in data analysis as a measure of global cognitive performance along with an impairment measure using the widely accepted cutoff of <26. 17 
The Stage of Mobility Dysfunction
To test our hypotheses regarding the association between the mobility dysfunctional stage and the cognitive performance, we created a variable that combines muscle strength and lower extremity (LE) performance to measure dysfunction at different stages of disablement. The handgrip strength (GS) was measured with a handheld dynamometer (Baseline Digital Smedley Spring Dynamometer; Patterson Medical, Warrenville, IL) in each hand and expressed in pounds (lbs), with the mean of the 2 being used in data analysis. GS correlates with other measures of muscle strength including LE strength 18 and is often used in aging studies as an indicator of the overall muscle strength. 19 Muscle impairment was defined as being in the bottom 20th sex-specific percentile of sample distribution. The mini Physical Performance Test (mPPT) 20 includes the following tasks: pick-up-penny, the 50-feet usual-pace walking test, 5 complete chair-raises, and the progressive Romberg balance test, each ranging from 0 to 4, with 4 indicating the highest level of performance. A score of <12 on this scale (range, 0 to 16) was used as an indicator of impaired LE performance. 20 As the progression of disablement 4 implies that a higher level dysfunction includes the presence of a lower level of dysfunction, we classified being impaired in both GS and LE performance as an indicator of later-stage mobility dysfunction. In contrast, impairment in either GS or LE performance would capture earlier stages of dysfunction. In this context, we considered the group with low GS but normal LE performance as having upper-extremity (UE) impairment, whereas those in the bottom 20th on the performance test as having LE impairment. The mPPT includes items that rely heavily on LE strength (such as a walking test, chair stands, picking up a penny from the floor, and balance), and therefore could be used as a measure of LE strength. Although UE strength is associated with LE strength, it accounts for only about 40% of the variation in LE strength, 21 supporting the idea that declines in UE and LE strength may represent similar but separate processes. Therefore, our staging variable includes the following 4 levels: 0 = no mobility dysfunction; 1 = UE impairment (ie, low GS but normal LE performance); 2 = LE impairment (low LE performance but normal GS); and 3 = mobility limitation (ie, low GS and low LE performance).
Covariates
Potentially important covariates were included in the analyses: increasing age (in years), sex (female vs. male), and the racial/ethnicity status (1 = non-Hispanic white, 2 = non-Hispanic black, 3 = Hispanic). Education was not included as a covariate due to its collinearity with the racial/ethnicity status in this sample. The body mass index (BMI = weight/ height 2 ), the proportion of visceral fat and muscle mass (expressed in lbs) derived from a bioelectrical impedance analysis with the BC-558 Ironman Segmental Body Composition Monitor (Tanita Corporation, Arlington Heights, IL), and the abdominal and hip girth were measured, and their ratio was used as a covariate; the total number of comorbid medical conditions (including cardiovascular risk factors and conditions spanning multiple body systems) was ascertained by a self-report as a part of the medical history. Finally, given the coexistence of a depressive symptomatology with poor physical 22 and cognitive function, 23 we also included depression as measured by the Hospital Anxiety and Depression Scale 24 as a covariate.
Data Analysis
Relationships between covariates, predictors, and outcomes were assessed with the w 2 test, variance analysis, or correlation analysis depending on the level of measurement to help identify potential covariates to be included in further analyses (Tables 1 and 2 ). MoCA scores were linearly regressed on the 4-level predictor variables controlling for the effect of significant covariates and potential mediators (Table 3 ). We used a multiple hierarchical approach in which the effect of the stage of mobility dysfunction on the outcome was initially assessed in an unadjusted model (model 1). To this model, sociodemographic and health factors were added to assess the impact of expected confounding factors (model 2). In the final model, mood was added to model 2 to determine its potential mediating role (model 3). In addition, the likelihood of cognitive impairment was estimated with logit regression modeling using the same hierarchical approach. Given the hypothesized progressiveness and dynamicity of the disablement process and the role that cognitive impairment might play, we then separated the 2 components of mobility impairment (muscle strength and LE performance) to investigate their mediating role as a means of assessing the directionality of the cognition-mobility association. A potential mediating role for muscle strength for example would likely reflect an initiator role of cognitive impairment (cognitive impairment leads to muscle strength loss and in turn to poorer extremity performance). Similarly, mediation by LE performance would suggest a cognitive impairment as a consequence of mobility impairment role. In the latter context, age-related muscle loss is expected to lead to poor LE performance and disability (not measured in the current study), which in turn may lead to cognitive loss. These mediation analyses were conducted using bootstrapping techniques (SAS code available from http://www.afhayes. com/spss-sas-and-mplus-macros-and-code.html), which involves resampling the data multiple times (we used 1000 resamples) to obtain an empirical estimation of the indirect effects across the resamples with confidence intervals around it to assess its statistical significance 25 (Fig. 1 ). Advantages of this technique include the obtainment of a quantitative indirect effect and lax requirements regarding the sampling distribution of indirect effects. Finally, sensitivity analyses were used to assess the impact of (1) including middle-aged individuals and (2) those with missing data on the outcome and the predictor.
RESULTS
Sample characteristics across the 4 groups are presented in Table 1 . More than half of the participants had no mobility impairment, whereas about 10% had UE impairment, 24% had LE impairment, and 10% had mobility limitations (both UE and LE impairments). Participants with indication of mobility limitation were significantly older and less likely to be white than the other groups. They also had significantly more visceral fat, lower muscle mass, and performed the poorest on MoCA. Modeling strategies regarding potential covariates to be included in further analyses were based on these associations as well as those revealed by inspecting correlation coefficients among the different measured factors, suggesting specific effects (eg, age, race/ethnicity, body composition, disease burden) that should be accounted for when assessing the mobility-cognition association ( Table 2) . BMI was not considered as a covariate of interest in this analysis on the basis of a lack of association with either the outcome or the predictor. The girth ratio was the only body composition measure included in model 2 in light of its larger impact on MoCA and relatively large collinearity with visceral fat. To minimize the risk of type II error, we included disease burden as a potential correlate on the basis of an a priori assumption of an impact on cognitive function despite a weak effect on the outcome. General linear models revealed a significant trend toward a stepwise association with a smaller impact of early versus later stages of physical dysfunction on the cognitive performance (Table 3 ). In the first model, unadjusted MoCA scores decreased by a factor of À2 in the UE impairment group, but by >4-fold in the mobility limitation group, with the LE impairment group faring in the middle. Adjustment for sociodemographic, body composition, and health factors reduced these effects only slightly. The inclusion of depressive symptoms had no impact. Similar results were obtained when the likelihood of cognitive impairment was assessed using the same modeling strategy (model 3). Figure 1 presents the results of our bootstrapping analyses investigating muscle strength as a mediator of the cognition-LE performance association, and separately LE performance as a mediator of the GS-cognition association. We found a significant association between the predictor, the mediator, and the outcome in both associations assessed. When the former association was assessed, the effect of the predictor (ie, MoCA) on the outcome (ie, LE performance) was reduced by 16% ((c path Àc 0 path)/c path), whereas in the case of the latter association, an 85% reduction in the effect of the predictor (ie, GS) on the outcome (ie, MoCA) was noted when the 2 mediators were included (muscle strength and LE performance, respectively). The nonsignificant c 0 term for the effect of GS on MoCA suggests that its effect is due entirely to an impact on the mobility performance, whereas the effect of MoCA on mobility performance is only partially due to lower MS in those with a poorer cognitive performance. Adjustment for confounders and potential mediators had no impact on the indirect effect of GS on MoCA and reduced the indirect effect of MoCA on LE performance only slightly from 0.031 to 0.027 (13% reduction), which remained significant (bias corrected 95% CI, 0.014-0.045).
DISCUSSION
Our results suggest that the association between cognitive function and mobility follows a dose-response format, with increasing likelihood of poor cognition as an individual progresses through different stages of mobility dysfunction. Although our data support associations suggested by the Central Benefit Model, we also found evidence that LE impairment may better capture the effects of mobility impairment on cognition than UE impairment as measured by low GS and that these effects likely operate in both directions. This is encouraging as evidence of a connection between poor cognitive performance and early-stage mobility dysfunction suggests that strategies to prevent future physical limitations and disability in individuals with low cognitive function may be more efficient when focused on addressing events that constitute the first steps in the disablement process. This in turn may reduce the risk of further cognitive decline and potentially the development of dementia possibly through an effect on other health-related factors.
Associations between cognition and different measures of mobility have been long recognized. Individuals with evidence of impaired cognitive function tend to perform poorly on physical tests. 26 Even in older adults without evidence of cognitive impairment, faster performance on mobility tests is associated with better cognitive abilities. 27 This strong link between cognitive function and mobility has been interpreted as suggestive of an underlying aging process that accounts for declines observed across various systems including cognition and physical function. 28 Results pooled from longitudinal studies, however, suggest that although changes in physical and cognitive functioning are associated, the evidence is not consistent enough to provide support for the common cause hypothesis, but rather suggests a true dynamic relationship between these changes in which the temporal ordering may operate in both directions. 29 The authors of the latter meta-analysis, however, acknowledge the general lack of studies that directly assessed the order of decline and indicated the need for a detailed examination of the direction in which these changes occur.
Within the confines of a cross-sectional analysis, our mediation findings provide support for the idea that the longitudinal association between the cognitive and the physical aspects of functioning is likely to operate in both directions. Using bootstrapping as the mediation approach, we found strong evidence that poor cognitive performance may lead to poor physical performance directly, but also indirectly through its impact on muscle strength. Similarly, we found that poor muscle strength is associated with poor cognition, mostly through the effect on LE (mobility) performance. We interpreted these indirect effects as an evidence of temporal ordering favoring the idea of dynamicity of the longitudinal association between cognitive and physical function in old age. These relationships should be examined in longitudinal studies that are better equipped to separate between-person from within-person changes and use other complex analytical methods to correct for bias and allow the fitting of alternative models of change. 29 The public health relevance of our findings suggests that the association between mobility and cognitive impairment follows a step-wise pattern. Although the strongest association may be observed between dementia and mobility disability (ie, an inability to perform mobilityrelated activities of daily living), it has been previously suggested that early measures of mobility dysfunction such as poor muscle strength can be used to identify individuals with poor cognitive performance who may be at risk for the development of future cognitive impairment and dementia. While a consistent association between cognition and mobility has already been reported, 5, [30] [31] [32] what previous work failed to establish is a clear link between the stage of mobility dysfunction and cognitive abilities and the pattern in which it unfolds. Although poor muscle strength can be used as an indication that the person may have reached the first stage of mobility dysfunction, the possibility that the person may in fact be much further down the process cannot be ruled out unless measures of dysfunction at more advanced stages are also taken into account. To address this issue, we constructed a variable that combines muscle strength and physical performance to better identify the stage of dysfunction in which participants fit best. Given the progressive nature of disablement in which downstream events rely on the presence of upstream events and also the multifactorial nature of poor physical performance, 21 this categorization scheme allows the separation of physical impairment and limitation stages and supports a further subcategorization of the impairment state.
Most importantly, the dose-response association observed between the stage of mobility dysfunction and cognitive performance suggests that progression through the disablement process (ie, progressing from impairment to limitation to disability) corresponds to worsening cognitive functioning. Taken together, these associations suggest that progression through the stages of physical disablement coincides with progression to dementia, which, given the bidirectional nature of the association as evidenced by our mediation analyses and other previous work, 29 indicates the potential for targeting individuals with early evidence of dysfunction in either aspect of functionality for interventions to mitigate or prevent decline and progression in the other.
Although our modeling approach does not allow us to distinguish confounders from mediators clearly, the interpretation depending on a priori assumptions, the lack of an impact of depression (our assumed mediator) suggests that other factors may help better clarify the mechanistic pathways linking physical dysfunction to cognitive impairment including physical inactivity, 14, 15 stress, and inflammatory processes. 16 Clarification of these likely complex mechanisms would inform interventions designed to maintain functionality and prevent both physical and cognitive decline.
Limitations of our study need to be considered when interpreting these results. First, the cross-sectional design of our study does not allow us to establish, but rather to suggest, a temporal ordering of decline in 2 aspects of functionality. We were able to demonstrate that late-stage mobility dysfunction is associated with the poorest cognitive performance. However, whether physical impairment was the result of cognitive decline or actually triggered the cognitive decline could not be determined in our study, although our mediation results were indicative of both scenarios being possible. Second, the inclusion of middleaged adults may raise questions of whether our physical performance measure, validated for use in older populations, would lead to ceiling effects in this subgroup. However, of the 98 participants younger than 65 years, only 1 scored a perfect 16 on the mPPT, suggesting limited ceiling effects. These findings are in line with other reports of good performance of similar measures in nondisabled middle-aged adults. 33 Moreover, when we excluded participants younger than 65 years, the results remained unchanged (eg, Est. UE = À0.55 ± 1.23, P = 0.655; Est. LE = À 2.46 ± 0.90, P = 0.007; Est. ML = À3.57 ± 1.27, P = 0.005 for the fully adjusted model predicting cognitive performance). Third, excluding participants with missing data on either the outcome or/and the predictor of interest could have an impact on our findings, especially in light of significant differences in the mean MoCA performance (18.5 ± 4.0 vs. 22.6 ± 5.4 for missing and nonmissing, respectively, P = 0.013). To address this, we replaced their missing data with the sample mean (ie, MoCA) or sample median (ie, the stage of mobility dysfunction) and reassessed the association between the mobility dysfunction stage and MoCA performance. Results remained unchanged (unadjusted model: Est. UE = À1.69 ± 0.99, P = 0.089; Est. LE = À3.19 ± 0.67, P < 0.001; Est. ML = À 3.89 ± 0.96, P < 0.001). Further adjustment had little impact on the results. Fourth, we assumed that the presence of poor LE performance in the absence of GS impairment may be considered as an indicator of LE impairment. This state may alternatively reflect orthopedic problems or chronic pain syndromes that do not affect either muscle strength or cognition or other factors such as low motivation or confidence in the ability to perform functional tests rather than "true" physical limitations as these would require the presence of impairments such as poor muscle function. 34, 35 This possibility highlights the importance of finding ways to better separate the motivational component of physical performance from the actual physical inability to perform physical tasks. Advantages include the relatively large sample size of multicultural, community-dwelling older adults, the use of validated tools to measure mobility and cognitive function, and our staging of mobility dysfunction strategy, which reduces the likelihood of miscategorization.
Our findings support the idea of a complex association between cognition function and mobility in later life in which mobility decline may reflect pathologic changes in the brain, but may also lead to further cognitive decline, in turn resulting in even more physical decline. Finding ways to mitigate this vicious cycle of mobility decline is imperative as it may help alleviate the burden of disability and dementia, the leading causes of distress in older adults and those caring for them. Using brief, valid tools to screen older patients for early signs of mobility dysfunction is feasible and may provide the first detectable stage of future cognitive impairment. Physical performance measurements, particularly those measuring the physical performance, should be encouraged during routine annual wellness examinations as this may help identify those in the early stages of cognitive impairment for whom interventions to improve symptoms and prevent the development of physical disability and loss of independence may be more successful.
